What is the current price and trend for ALC.SW stock?

ALC.SW stock trades pre-market at **CHF60.48**, down **2.39%** on 04 Feb 2026. The stock sits below its 50-day average, signaling short-term resistance for most-active traders.

How does Meyka AI grade ALC.SW stock and what does it mean?

Meyka AI rates ALC.SW with a score out of 100: **70.96 | Grade B+ | Suggestion: BUY**. The grade mixes benchmark, sector, growth and metric analysis and is for informational use only.

What price targets and forecast exist for ALC.SW stock?

Meyka AI's forecast model projects **monthly CHF59.57**, **quarterly CHF61.27**, and **yearly CHF58.39**. Scenario targets: near-term **CHF63.00**, 12-month **CHF68.00–CHF75.00**, depending on surgical recovery.

What are the main risks for ALC.SW stock investors?

Key risks for ALC.SW stock include valuation compression (PE **37.33**), surgical demand cyclicality, long inventory days, and execution risks on new product rollouts.

CH Stocks

ALC.SW Alcon down 2.39% pre-market 04 Feb 2026: CHF60.48 near 50d support

ByHuzaifa Zahoor February 4, 2026February 4, 2026

Pre-market trading shows ALC.SW stock at CHF60.48, down 2.39% on 04 Feb 2026 as volume runs above average. The move follows mixed sector cues and a product launch, and leaves the price close to the 50-day average CHF63.37. We note PE 37.33 and EPS 1.62, which frame valuation questions ahead of the next earnings date. This pre-market snapshot matters for most-active traders on the SIX in Switzerland and for portfolio managers tracking healthcare names.